Carole Ho - Net Worth and Insider Trading

Carole Ho Net Worth

The estimated net worth of Carole Ho is at least $9 Million dollars as of 2024-11-05. Carole Ho is the Chief Medical Officer of Denali Therapeutics Inc and owns about 327,029 shares of Denali Therapeutics Inc (DNLI) stock worth over $9 Million. Details can be seen in Carole Ho's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Carole Ho has not made any transactions after 2024-08-21 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Carole Ho

Carole Ho Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Carole Ho owns 3 companies in total, including Denali Therapeutics Inc (DNLI) , NGM Biopharmaceuticals Inc (NGM) , and Beam Therapeutics Inc (BEAM) .

Click here to see the complete history of Carole Ho’s form 4 insider trades.

Insider Ownership Summary of Carole Ho

Ticker	Comapny	Transaction Date	Type of Owner
DNLI	Denali Therapeutics Inc	2024-08-21	Chief Medical Officer
NGM	NGM Biopharmaceuticals Inc	2020-06-05	director
BEAM	Beam Therapeutics Inc	2020-02-05	director

Carole Ho Latest Holdings Summary

Carole Ho currently owns a total of 1 stock. Carole Ho owns 327,029 shares of Denali Therapeutics Inc (DNLI) as of August 21, 2024, with a value of $9 Million.

Latest Holdings of Carole Ho

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
DNLI	Denali Therapeutics Inc	2024-08-21	327,029	27.21	8,898,459

Holding Weightings of Carole Ho

Carole Ho Form 4 Trading Tracker

According to the SEC Form 4 filings, Carole Ho has made a total of 30 transactions in Denali Therapeutics Inc (DNLI) over the past 5 years, including 0 buys and 30 sells. The most-recent trade in Denali Therapeutics Inc is the sale of 22,458 shares on August 21, 2024, which brought Carole Ho around $549,996.

Insider Trading History of Carole Ho

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Carole Ho Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Carole Ho Ownership Network

Ownership Network List of Carole Ho

No Data

Ownership Network Relation of Carole Ho

Carole Ho Owned Company Details

What does Denali Therapeutics Inc do?

Who are the key executives at Denali Therapeutics Inc?

Carole Ho is the Chief Medical Officer of Denali Therapeutics Inc. Other key executives at Denali Therapeutics Inc include director & President and CEO Ryan J. Watts , CFO and Treasurer Steve E. Krognes , and COO and Secretary Alexander O. Schuth .

Denali Therapeutics Inc (DNLI) Insider Trades Summary

Over the past 18 months, Carole Ho made 9 insider transaction in Denali Therapeutics Inc (DNLI) with a net sale of 54,249. Other recent insider transactions involving Denali Therapeutics Inc (DNLI) include a net sale of 25,506 shares made by Vicki L Sato , a net sale of 83,768 shares made by Alexander O. Schuth , and a net sale of 131,985 shares made by Ryan J. Watts .

In summary, during the past 3 months, insiders sold 113,507 shares of Denali Therapeutics Inc (DNLI) in total and bought 0 shares, with a net sale of 113,507 shares. During the past 18 months, 459,258 shares of Denali Therapeutics Inc (DNLI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 459,258 shares.

Denali Therapeutics Inc (DNLI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Denali Therapeutics Inc Insider Transactions

No Available Data

What does NGM Biopharmaceuticals Inc do?

Who are the key executives at NGM Biopharmaceuticals Inc?

Carole Ho is the director of NGM Biopharmaceuticals Inc. Other key executives at NGM Biopharmaceuticals Inc include director & 10 percent owner David V Goeddel , 10 percent owner Column Group L P , and Chief Financial Officer Jean-frederic Viret .

NGM Biopharmaceuticals Inc (NGM) Insider Trades Summary

Over the past 18 months, Carole Ho made no insider transaction in NGM Biopharmaceuticals Inc (NGM). Other recent insider transactions involving NGM Biopharmaceuticals Inc (NGM) include a net purchase of 67,893 shares made by Column Group L P , and a net purchase of 26,811 shares made by David V Goeddel .

In summary, during the past 3 months, insiders sold 0 shares of NGM Biopharmaceuticals Inc (NGM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NGM Biopharmaceuticals Inc (NGM) were sold and 94,704 shares were bought by its insiders, resulting in a net purchase of 94,704 shares.

NGM Biopharmaceuticals Inc (NGM)'s detailed insider trading history can be found in Insider Trading Tracker table.

NGM Biopharmaceuticals Inc Insider Transactions

No Available Data

What does Beam Therapeutics Inc do?

Who are the key executives at Beam Therapeutics Inc?

Carole Ho is the director of Beam Therapeutics Inc. Other key executives at Beam Therapeutics Inc include President & CSO Giuseppe Ciaramella , Chief Legal Officer Christine Bellon , and director & CEO John M. Evans .

Beam Therapeutics Inc (BEAM) Insider Trades Summary

Over the past 18 months, Carole Ho made no insider transaction in Beam Therapeutics Inc (BEAM). Other recent insider transactions involving Beam Therapeutics Inc (BEAM) include a net sale of 16,081 shares made by Christine Bellon , a net sale of 198,102 shares made by John M. Evans , and a net sale of 28,776 shares made by Amy Simon .

In summary, during the past 3 months, insiders sold 111,784 shares of Beam Therapeutics Inc (BEAM) in total and bought 0 shares, with a net sale of 111,784 shares. During the past 18 months, 1,362,433 shares of Beam Therapeutics Inc (BEAM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,362,433 shares.

Beam Therapeutics Inc (BEAM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Beam Therapeutics Inc Insider Transactions

No Available Data

Carole Ho Mailing Address

Above is the net worth, insider trading, and ownership report for Carole Ho. You might contact Carole Ho via mailing address: C/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco Ca 94080.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.